Moderna and Merck's mRNA cancer vaccine shows promise in reducing risk of melanoma relapse.

Moderna and Merck plan to launch a Phase III study this year for their personalized cancer vaccine in melanoma, and have revealed more details from a Phase IIb test that earlier this year renewed excitement about the use of vaccines in fighting tumors. AstraZeneca posted event-free survival data on Imfinzi’s use before and after surgery in patients with non-small cell lung cancer on Sunday, with its rival Merck months away from an FDA decision in the same indication.